Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes — MyCancerGene  

Cancer Clinical Trial

Official title: Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes

Status Not yet recruiting

Clinical Trial Summary

This protocol aims to evaluate the efficacy of a theoretically and stakeholder informed patient-centered genetic Interactive Health Communication Application to increase patient understanding of, and affective and behavioral responses to genetic testing. We hypothesize that the intervention will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in performance of risk reducing health behaviors.

Clinical Trial Description

As we increasingly use multi-gene testing in clinical practice, many patients are left with unknowns after genetic testing. Many have results that are unclear and may or may not be associated with any risk for cancer (Variants of Uncertain Significance), or mutations in genes with very limited information about disease risk or the best medical management Importantly, many of these uncertainties will be clarified over time, but we need effective ways of communicating these updates to patients who had testing months or years ago. In some cases, there may be multiple updates over time. To address this study will provide patients access using an Interactive Health Communication Application, MyCancerGene, to information about their genetic testing, their specific results and the implications, ability to print reports and other materials for their relatives and other health care providers and periodic reminders for cancer screening and to assess if there has been a change in the personal or family history. Additionally, patients can contact their genetic provider through MyCancerGene and the cancer genetics team can send out updates to patients about their individual results or about new information about risk estimates or screening recommendations. We hypothesize that MyCancerGene will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in cancer screening and risk reducing health behaviors. After 18 months, all patients will have access to MyCancerGene, which will help us understand who benefits most and least from this intervention. ;

Related Conditions & MeSH terms

• Cancer

• NCT number: NCT04369196
• Study type: Interventional
• Source: Abramson Cancer Center of the University of Pennsylvania
• Contact: Angela R Bradbury, MD
• Phone: 215 615 3341
• Email: Angela.Bradbury@uphs.upenn.edu
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 2020
• Completion date: May 2025